Prime Medicine Inc (PRME)
7.085
+0.04
(+0.64%)
USD |
NASDAQ |
May 17, 16:00
7.085
0.00 (0.00%)
After-Hours: 20:00
Prime Medicine Enterprise Value: 639.10M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 639.10M |
| May 16, 2024 | 634.29M |
| May 15, 2024 | 600.69M |
| May 14, 2024 | 588.68M |
| May 13, 2024 | 559.87M |
| May 10, 2024 | 462.65M |
| May 09, 2024 | 475.85M |
| May 08, 2024 | 432.64M |
| May 07, 2024 | 457.85M |
| May 06, 2024 | 437.44M |
| May 03, 2024 | 460.25M |
| May 02, 2024 | 462.65M |
| May 01, 2024 | 421.84M |
| April 30, 2024 | 379.82M |
| April 29, 2024 | 372.62M |
| April 26, 2024 | 320.40M |
| April 25, 2024 | 305.40M |
| April 24, 2024 | 353.41M |
| April 23, 2024 | 365.42M |
| April 22, 2024 | 363.01M |
| April 19, 2024 | 330.61M |
| April 18, 2024 | 340.17M |
| April 17, 2024 | 380.98M |
| April 16, 2024 | 421.79M |
| April 15, 2024 | 442.19M |
| Date | Value |
|---|---|
| April 12, 2024 | 477.00M |
| April 11, 2024 | 486.60M |
| April 10, 2024 | 496.20M |
| April 09, 2024 | 531.01M |
| April 08, 2024 | 521.41M |
| April 05, 2024 | 479.40M |
| April 04, 2024 | 484.20M |
| April 03, 2024 | 485.40M |
| April 02, 2024 | 547.81M |
| April 01, 2024 | 600.62M |
| March 31, 2024 | 629.43M |
| March 28, 2024 | 717.91M |
| March 27, 2024 | 689.12M |
| March 26, 2024 | 677.13M |
| March 25, 2024 | 702.32M |
| March 22, 2024 | 709.51M |
| March 21, 2024 | 758.69M |
| March 20, 2024 | 762.29M |
| March 19, 2024 | 731.10M |
| March 18, 2024 | 720.31M |
| March 15, 2024 | 737.10M |
| March 14, 2024 | 704.12M |
| March 13, 2024 | 829.45M |
| March 12, 2024 | 803.07M |
| March 11, 2024 | 841.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
305.40M
Minimum
Apr 25 2024
2.302B
Maximum
Nov 11 2022
1.036B
Average
982.36M
Median
Aug 14 2023
Enterprise Value Benchmarks
| Pacific Biosciences of California Inc | 880.79M |
| 10x Genomics Inc | 2.622B |
| Recursion Pharmaceuticals Inc | 1.944B |
| Verve Therapeutics Inc | -104.25M |
| Ginkgo Bioworks Holdings Inc | 940.97M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -45.76M |
| Revenue (Quarterly) | 0.591M |
| Total Expenses (Quarterly) | 48.93M |
| EPS Diluted (Quarterly) | -0.44 |
| Profit Margin (Quarterly) | -7.74K% |
| Earnings Yield | -30.79% |